Royalty Pharma plc(RPRX)Q2 2026 法說會逐字稿

Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma's Second Quarter 2026 Earnings Conference Call. I would like now to turn the conference over to George Grofik, Senior Vice President, Head of Investor Relations and Communications. Please go ahead, sir.

Good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's second quarter results. You can find the press release with our earnings results and slides of this call on the Investors page of our website at royaltypharma.com. On Slide 2, I'd like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from these statements. We refer you to our most recent 10-K on file with the SEC for a description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma, and we assume no obligation to update any such forward-looking statements. Non-GAAP liquidity measures will be used to help you understand our financial results and the reconciliation of these measures to our GAAP financials is provided in the earnings press release available on our website. And with that, please advance to Slide 3. Our speakers on the call today are Pablo Legorreta, Chief Executive Officer and Chairman of the Board; Marshall Urist, EVP, Head of Research and Investments; Chris Hite, Chairman, Partnering and Investments; and Terry Coyne, EVP, Chief Financial Officer. Pablo will discuss the key highlights, after which Marshall will provide a portfolio update. Chris will then discuss our development stage pipeline, and Terry will review the financials. Following concluding remarks from Pablo, we will hold the Q&A session. And with that, I'd like to turn the call over to Pablo.

Thank you, George, and welcome, everyone. I am pleased to report another quarter of strong financial performance and disciplined execution. This is our 25th consecutive quarter as a public company with strong predictable double-digit growth, and we're achieving this as we continue to deliver on our goal of being the premier capital allocator in life sciences, driving consistent compounding growth. Slide 5 summarizes our strong business momentum in the second quarter. Starting with the financials, we delivered 6% growth in portfolio receipts, our top line, and 14% growth in total receipts, which are our recurring cash flows. Our top line performance was ahead of our guidance for the quarter and reflects the tremendous momentum of our diversified portfolio. We also maintained attractive returns in our business with return on invested capital of 14.2% and return on invested equity of 20.1%. By consistently delivering strong growth and superior returns, we believe we have a clear path to drive continued shareholder value creation. Turning to capital allocation, we have deployed $1.1 billion of capital on royalty acquisitions so far this year, with an announced value of $1.7 billion. Most importantly, we acquired a royalty on AstraZeneca's cliramitug, a potential blockbuster therapy for transthyretin amyloid cardiomyopathy. As we look ahead, our deal pipeline remains robust. Under our value-driven capital allocation framework, we also returned around $370 million to shareholders in dividends and share repurchases in the first half of the year. Moving to our portfolio, we continue to see a number of positive updates. Our partner Revolution Medicines completed its rolling submission for daraxonrasib in pancreatic cancer with accelerated review also underway in Europe. We were also delighted to see key regulatory approvals for Gilead's Trodelvy, GSK's Jideytro and Amgen's Imdelltra. We look forward to these therapies contributing to our top line in the years ahead. Looking ahead, we're increasing our 2026 full year guidance for the second consecutive quarter based on the strong business momentum I just highlighted. Slide 6 is one that I return to each quarter as it demonstrates our consistent double-digit growth on average since our IPO. We have delivered this impressive record year in and year out, regardless of the market backdrop. This reflects the quality of our asset selection and our unique business model. Slide 7, my final slide, underscores the quality of our diligence process and our deep understanding of the life sciences ecosystem. In short, we've been ahead of the curve in identifying some of the most exciting innovators. Nuvalent and MLX are just the latest examples of companies whose therapies we acquired royalties on that were subsequently acquired by large pharma companies. This, of course, validated our internal views of their programs and will also likely increase the value of our royalties as large pharma brings significant clinical resources and commercial scale. With that, I will hand it over to Marshall.

Thanks, Pablo. I want to focus today on our recent royalty deal for cliramitug, which is our second investment in TTR amyloidosis. Beginning on Slide 9, we recently acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million. The transaction was structured to include a $125 million upfront payment to Neurimmune and an additional $125 million payment in the first quarter of 2027 and up to $175 million payable on key clinical and regulatory milestones. In return, Royalty Pharma will receive a royalty of 3.75% on worldwide net sales. Cliramitug is a highly novel therapy for TTR amyloidosis with cardiomyopathy or ATTR-CM. ATTR-CM is an age-associated progressive disease in which misfolded TTR proteins accumulate in the heart, severely impacting heart function and ultimately survival. There are several approved therapies for this indication, including Amvuttra, our first investment in this indication. The approved therapies slow disease progression by preventing ATTR accumulation, but they do not impact the amyloid deposits that have already accumulated in the heart. As a first-in-class TTR fibril depleting antibody, cliramitug is designed to remove amyloid and potentially reverse the course of the disease, a clearly differentiated role for cliramitug with significant benefit for patients. The early clinical data for cliramitug are impressive. Phase I demonstrated strong amyloid clearance via biomarkers that correlate with improved cardiovascular outcomes. A Phase III outcomes trial is fully enrolled around 1,200 patients and results are expected in 2028. We see clear blockbuster potential for cliramitug in an expanding market, which was more than $7 billion last year. There are over 0.5 million patients worldwide with ATTR-CM, including around 200,000 in the U.S., and of these, around 80% of patients are untreated, underscoring the scale of the unmet need and the scope for market growth. AstraZeneca has provided peak annual sales for cliramitug of between $3 billion to $5 billion. Based on this, we would expect to generate an internal rate of return in the teens consistent with our development stage target range and peak annual royalties of approximately $110 million to $190 million based on AstraZeneca's peak sales expectations. Moving to Slide 10, this latest transaction is a compelling example of how Royalty Pharma builds significant therapeutic expertise over many years, allowing us to invest in the best potentially transformative medicines often across multiple products in the same class. In the case of ATTR, we've been closely following this therapeutic category over the past decade and have evaluated many of the therapies that are now approved. Our first investment was Amvuttra in 2025, which has had a strong launch in cardiomyopathy. With the addition of cliramitug to our portfolio, we now have two differentiated approaches to this serious rare disease. As you have seen us do this in many other indications such as prostate cancer, spinal muscular atrophy, immunology and multiple sclerosis. This ability to build a portfolio with multiple therapies in a category is unique to Royalty Pharma. When combined with our proven deep diligence, we are well positioned to invest in the most practice-changing and innovative therapeutic categories in the industry for years to come. With that, let me hand over to Chris.

Thanks, Marshall. In my section of today's presentation, I want to highlight the significant expansion of our development stage pipeline, together with important upcoming events across the portfolio. You can see on Slide 12 that we have achieved strong, consistent growth in our development stage pipeline since our IPO in June 2020. At that time, we had three potential therapies in the pipeline. Today, we have 19, a more than sixfold increase. More importantly, the peak royalty potential of our pipeline has increased by more than 30-fold over the period with peak potential royalties from our late-stage pipeline now totaling approximately $2 billion. We have also demonstrated an excellent success rate with around 90% of our development-stage investments ultimately achieving regulatory approval, which provides us confidence that these products will be an important driver of growth into 2030 and beyond. The track record of success is underscored by Slide 13, which shows that in addition to daraxonrasib, our portfolio has delivered a number of successful clinical readouts and regulatory events so far in 2026. These include positive clinical trial results for Cytokinetics' Myqorzo, Zenas' obexelimab and Biogen's litifilimab; FDA approvals of GSK's Jideytro, Denali's Avlayah and Gilead's Trodelvy as well as a number of FDA regulatory submissions. Expanding on this theme, Slide 14 shows there is much more to come from our development stage pipeline with several major pivotal trial readouts expected through 2027. In 2026, we expect to see the results of the outcomes trial for Novartis' pelacarsen. We continue to believe that the Lp(a) class could be the next major class of cardiovascular disease drugs, and we're strongly positioned to leverage this with the two lead pipeline products in pelacarsen and Amgen's olpasiran. We'll also see Phase III data for Biogen's litifilimab in systemic lupus. In 2027, we expect Phase III results from daraxonrasib in lung cancer and litifilimab in cutaneous lupus. We also expect pivotal data from Sanofi's frexalimab in MS and from J&J's seltorexant in major depressive disorder. Each of these potentially transformative therapies would add significant royalties to our top line. Taking a step back, when looking at these opportunities that we are currently evaluating, we are pleased to see a balanced opportunity set that includes both attractive approved products as well as exciting development stage opportunities across a range of potential partners. To finish, I want to provide context on the composition of our portfolio, which is broadly unchanged and remains well balanced. Slide 15 illustrates that we currently have around $22 billion of total invested capital at work with around 84% of either products which were approved when we invested or were development-stage assets which have gone on to receive approval. Additionally, while 12% of our current invested capital at work is in development-stage therapies, roughly one third of that capital at work has been invested in development stage programs that have already had positive pivotal results. This means that despite the expansion of our pipeline, our overall capital at work for development-stage therapies is relatively small. Furthermore, we have a great track record when investing in development-stage therapies, which reflects the quality of our diligence and asset selection. With that, I'd like to hand it over to Terry.

Thanks, Chris. Let's move to Slide 17. This slide shows how our efficient business model generates substantial cash flow to be reinvested. Royalty receipts grew by 14% in the second quarter, reflecting the strength of our diversified portfolio. Milestones and other contractual receipts, which are more variable, declined substantially reflecting a one-time payment in the prior year period. As a result, portfolio receipts, our top line, grew 6% in the quarter to $773 million, slightly ahead of our expectations. As we move down the column, operating and professional costs equated to 4.8% of portfolio receipts in the second quarter. This line continues to demonstrate the benefit of the cash savings we are delivering from the internalization transaction, which we completed in May of 2025. Net interest paid was de minimis in the quarter. This reflects the semiannual timing of our interest payment schedule with payments primarily in the first and third quarters, together with the interest we received from the cash on our balance sheet. Moving further down the column, we have consistently stated that when we think of the cash generated by the business to then be redeployed into value-enhancing royalties, we look to portfolio cash flow, which is adjusted EBITDA less net interest paid. This amounted to $736 million for the quarter. Our margin of around 95% again demonstrates the high underlying level of cash conversion and efficiency in the business. Capital deployment in the quarter of $349 million mainly reflected royalty funding for daraxonrasib and R&D funding for J&J's 4804 and litifilimab. Lastly, our weighted average share count declined by approximately 5 million shares or 1% in the quarter versus the prior year period, reflecting the impact of our share buyback program. Slide 18 provides more detail on the evolution of our top line in the second quarter. Royalty receipts, which we consider our recurring cash inflows, grew by 14%. Key drivers were the strong performances of Tremfya, Voranigo, Imdelltra and Evrysdi. Importantly, as we saw in the first quarter, we were able to absorb significant headwinds from Promacta and Imbruvica and still delivered double-digit growth in royalty receipts. Moving to portfolio receipts, these grew by 6% reflecting lower milestones and other contractual receipts given a one-time payment in the prior year period, as I already noted. Slide 19 updates our portfolio return metrics for the quarter. Return on invested capital was 14.2% for the last 12 months ending in the second quarter of 2026, and return on invested equity, which shows the impact of conservative leverage on our equity returns, was 20.1% for the last 12 months. The remarkable stability of these metrics demonstrates that we are continuing to invest at attractive returns that will drive long-term value for our shareholders. Slide 20 shows that we continue to maintain the financial flexibility to execute our strategy and return capital to shareholders. At the end of June 2026, we had cash and equivalents of $812 million. In terms of borrowings, we had investment grade debt outstanding of $9.2 billion with a weighted average duration of around 12 years. Our leverage now stands at 2.8x total debt to adjusted EBITDA, or 2.6x on a net basis. We also have access to our $1.8 billion revolver, which was undrawn at the end of the second quarter. Following S&P's rating upgrade in June, I am delighted to say that Royalty Pharma is now BBB rated across all major credit rating agencies. This important milestone reflects the tremendous progress we have made as a company since our IPO, including our consistent strong top line growth, improved diversification and growing cash flows. For financial capacity, we have access to over $4 billion of financial flexibility through cash on our balance sheet, the cash our business generates and access to the debt markets. Turning to our capital allocation framework, we deployed $877 million of capital on attractive royalty deals in the first half of 2026. At the same time, we returned approximately $367 million to our shareholders, including share repurchases of around $100 million. In total, we have returned about 25% of our portfolio cash flow this year to shareholders. On Slide 21, we are again raising our full year 2026 financial guidance. We now expect portfolio receipts to be in the range of $3.4 billion to $3.5 billion, up from $3.325 billion to $3.45 billion previously. This assumes growth in royalty receipts of around 7% to 10% compared with 4% to 8% previously, which reflects the strong underlying momentum of our diversified portfolio. This guidance takes into account the loss of exclusivity for Promacta as well as the launch of biosimilar Tysabri in the United States and the potential impact of IRA. It also reflects an expected decrease in milestones and other contractual receipts from $128 million in 2025 to approximately $60 million in 2026. Importantly and consistent with our standard practice, this guidance is based on our portfolio as of today and does not take into account the benefit of any future royalty acquisitions. Turning to expenses, payments for operating and professional costs are still expected to be in the range of 5.5% to 6.5% of portfolio receipts in 2026, reflecting cost savings from the internalization of the manager. We continue to expect interest paid to be around $350 million to $360 million in 2026. Based on our semiannual payment cycle, we anticipate interest paid to be around $175 million in the third quarter, with a de minimis amount payable in Q4. This guidance reflects repayment of the $380 million term loan in July but does not take into account interest received on our cash balance, which was $11 million in the first half. To close, we've had a great first half. We have again raised our guidance, and we expect to continue to deliver another full year of strong financial performance in 2026. With that, I would like to hand the call back to Pablo.

Thanks, Terry. To conclude, I am delighted with our continued execution against our strategy in the first half of 2026. We have again delivered compelling growth and returns. We further diversified our portfolio of attractive biopharma royalties, and we have continued to strengthen our leadership team and capabilities. On that note, I want to close on Slide 23 with a reminder of why we believe we're well positioned to drive continued strong value creation. First, we're the clear leader in the rapidly expanding biopharma royalty market with powerful fundamental tailwinds, reflecting the huge demand for funding life sciences innovation. Second, we have a best-in-class platform for investing in the most transformative and innovative products marketed by premier biopharma companies. By expanding our global platform and capabilities, we expect to remain the undisputed leader in our industry. We further strengthened our platform with the addition of Greg Raskin to lead our academic royalty effort. Greg is uniquely qualified to lead work with academic partners, having led the technology transfer group at Memorial Sloan Kettering for 12 years. I continue to be amazed by the level of talent we're able to attract to Royalty Pharma. Third, we expect to deliver strong, low volatility top line and bottom line growth through 2030 and beyond. Lastly, we have an incredible track record of delivering consistent and attractive returns, including an IRR and return on invested capital in the mid-teens and return on invested equity in a 20% plus range. With that, we will be happy to take your questions.

Thanks, Pablo. And we will now open up the call to questions. Operator, please take the first question.

The first question comes from Geoff Meacham with Citi.

I got a couple for you, Terry. We've seen a big step-up in pharma to biotech M&A and maybe there's some pharma to pharma M&A to come. The question is, what is the flexibility to tilt your deal structure with increasing weight on equity? Is there any preference by the companies? And the second question is, does your credit rating, which you cited is improving, or the direction of rates downward, bias you to put more money to work each quarter? It seems like you could be more opportunistic here.

Sure, Geoff. We highlighted that we have a lot of financial flexibility. To the extent that some of the M&A across the sector creates opportunities, which it certainly could, we feel like we are in a really great position to partner with these companies in any way that they need and add royalties for Royalty Pharma. So yes, we'll see how that plays out over time. As far as rates, we are agnostic to the rate environment. When rates were rising over the last couple of years, we deployed a lot of capital and generated great returns in excess of our cost of capital. If rates start going down, we still feel like we can deploy capital and generate great returns. We will continue to access the debt markets from time to time when we need it with a very strong focus on maintaining that investment grade rating. We're really happy that we're now BBB rated across all three agencies.

The next question will come from Terence Flynn with Morgan Stanley.

This one is probably for Marshall. The recent CARDIO-TTRansform data created some questions in the TTR market. You recognize that you guys have a multidrug portfolio approach here. But just high-level thoughts on implications for Amvuttra as you think about the forward outlook here. And then again, maybe for Chris, would be curious, any update on the synthetic royalty opportunity in terms of those — the level of discussions or openness for boards to go down that path? I know you guys have talked about the longer-term opportunity, but just curious to get kind of a mark-to-market.

Thanks, Terence. On the implications of CARDIO-TTRansform, at a high level, we're very happy with the two investments we have in TTR amyloidosis. This remains a very interesting market, and we added something highly novel and potentially transformative in cliramitug, as I discussed. Specifically regarding Amvuttra, we think there is still a lot of physician interest and potential in that product. It is unique in the sense that it is positioned in some ways to drive at least some benefit from the unfortunate outcome of CARDIO-TTRansform, which, of course, is never welcome when trials fail for patients. Specifically with Amvuttra, it does reduce a near-term competitor. Because our royalty is specific to Amvuttra and not Alnylam's follow-on, if there is any delay or other changes in the expectations for the follow-on product vutrisiran, that would also uniquely accrue to the benefit of Amvuttra. So we are excited about where we stand, and we'll continue to look for opportunities like cliramitug to build our innovative portfolio.

Terence, on synthetics, we are still very excited about the synthetic royalty opportunity. Last year, we announced synthetics for just over $2 billion, including the RevMed deal, one of the largest synthetics ever. The growth rate in the synthetic marketplace has been around 40% since 2015. Last year was the biggest year ever, just under $5 billion for the product itself. The synthetic royalty opportunity only really represents about 5% of the capital raised by biopharma funding over the last five years, so it has not been heavily penetrated. Given all the clear advantages of synthetics — nondilutive, lower cost of capital, program-specific funding, independent valuation validation — there are many advantages. Our survey of biotech CFOs and CEOs shows it's taking hold, and we're very excited about the opportunity to see it as a significant growth driver for our business.

The next question will come from Chris Schott with JPM.

On Slide 15, you highlighted invested capital split kind of two-thirds approved and one-third development stage over time. As Royalty has grown, you've built out a broader team and have more ability to diligence assets. Is there any interest in leaning more into the development stage side of the business where returns could be higher, or is this two-thirds, one-third mix the right balance if we think about risk versus return? And then maybe a second question, you've been building more of a presence in China. Any updates in terms of initial learnings as you've targeted that market? What type of opportunities do you see for Royalty? Does that skew towards larger deals or some JV assets or more towards smaller earlier-stage businesses there?

Regarding the split between unapproved and approved, that 65/35 ratio has been consistent over the last five to ten years. We look at this over a rolling two- to three-year period and expect it to be maintained at a relatively similar level. The amount invested in unapproved assets is relatively low at about 12% of total invested capital; that number could trend up to the mid- to high-teens and still be a portfolio with relatively low risk. We would be comfortable with that kind of shift. Regarding China, it's early days in terms of capital deployed. We've been paying attention to that market for several years and hired a top player for the market. We have started to get more active, participating in conferences and meeting with companies. I will be going to China to meet with biotech and biopharma CEOs to ensure our model is understood and to build the market. It takes time, but we're committed to building that market because we believe it's attractive and large. We will be patient as this develops.

The next question will come from Michael Nedelcovych with TD Cowen.

Two questions. First, what was the reason for relatively low operating costs in Q2, and given that guidance was reiterated for this line, what will be the reason for an apparent increase in the second half? Second, Pablo, in a recent meeting when you were asked about competition, you suggested that, given the opportunity today, even you would not be able to build a new competitor that resembled Royalty Pharma. Could you remind us of your reasons for that view and why investors should not be concerned about the emergence of a competitor with the same form, function and scale as Royalty Pharma?

I'll take the competitive question and then Terry will address operating costs. When you look at Royalty Pharma today, there are many barriers to entry. Scale is important; we have around $22 billion of capital at work. The portfolio we have today produces substantial recurring revenue—$3.2 billion last year—and it took us over a decade to assemble that portfolio. Many of our royalties are one-of-a-kind assets: there is only one Tremfya royalty and we own it, one Trelegy royalty and we own it. Those are irreproducible. Our pipeline also represents the result of years of work to assemble unique assets that could be blockbusters. Even if someone had $20 billion or $30 billion of capital, it would be essentially impossible to replicate Royalty Pharma in a short time frame because it's the product of decades of execution, relationships, team building and unique, irreplaceable assets. That creates a very large moat and barrier to entry.

On operating costs, we are realizing the synergies from the internalization transaction. Regarding first half versus second half, there's some seasonality to operating costs. Since this is completely cash-based, the second half tends to be a little higher than the first half, which explains the difference.

The next question comes from Ash Verma with UBS.

Congrats on the quarter. First, going back to Slide 15, can you remind us what type of IRR you are able to drive in the development stage assets versus the approved assets? Second, on the Lp(a) readout for pelacarsen, any thoughts on what level of MACE risk reduction would be clinically meaningful? Does that change in the high baseline Lp(a) subgroup?

Thanks, Ash. On return expectations, for approved or on-market products our unlevered IRR expectations are in the high single to low double-digit range, and we're typically investing at the higher end of that range. For unapproved products, our IRR expectations are in the teens, depending on product specifics, risk profile and counterparty. These are unlevered IRR expectations; because of our capital structure and ability to use leverage, the levered returns that shareholders enjoy are significantly higher. On pelacarsen, there's been a lot of discussion about what would be clinically meaningful. We are eagerly awaiting the results. Novartis has been explicit about its expectations for clinical relevance, and this trial is the first outcome study that will be broadly informative for the Lp(a) class. We'll learn much about benefit and subgroup effects, including what higher baseline Lp(a) means for patient benefit. We look forward to discussing the data once it is available.

The next question will come from Umer Raffat with Evercore.

This is Mike DiFiore in for Umer. Two questions. For the cliramitug transaction, the royalty is ultimately dependent on the Phase III cardiovascular outcomes trial. Perhaps walk us through how you handicap Phase III based on the Phase I biomarker effects as well as the existing correlation data, given the unproven mechanism. Second, regarding R&D co-funding, as that scales how do you prevent adverse selection where partner companies retain the programs with the best internal risk-adjusted returns and offer you those with less favorable biology or commercial optionality?

We were very happy to add cliramitug to our portfolio. Our enthusiasm is supported by intriguing biomarker data from early studies, including imaging data showing removal of amyloid from the heart and biomarker improvements such as NT-proBNP reductions consistent with reduced cardiac wall stress. Historically, every product in TTR amyloidosis has gone into a Phase III outcomes study based on biomarker data, and we've seen biomarker improvements translate into cardiovascular benefit with oral therapies and with Amvuttra. Additionally, data from other amyloid diseases, such as Alzheimer's and AL amyloidosis, suggest that amyloid removal can drive clinical benefit. AstraZeneca has recently shown interesting data with another amyloid depleter in AL amyloidosis, which supports the idea that depletion can translate to outcome benefit. We put all of these lines of evidence together to inform our confidence in cliramitug's potential.

On adverse selection and R&D co-funding, it's an important question. We emphasize in every initial discussion with pharma that our bar is extraordinarily high. We deploy significant capital in these transactions, as shown by the deals with Teva and J&J this year, and we insist on funding their most exciting assets. Sometimes we initiate conversations saying what we want to fund; sometimes pharma approaches us. In every situation, we are disciplined and focus on funding the most promising programs, which mitigates adverse selection risk. The recent deals demonstrate that approach in practice.

The next question will come from Nick Jennings with Goldman Sachs.

Congrats on the performance. First for Terry, in light of continued strong results over the past few quarters, how are you tracking towards the $4.7 billion portfolio receipts target for 2030 and if you are thinking of potentially updating that? Second, for Marshall, you noted you place multiple bets in the same therapeutic areas. What emerging therapeutic areas are catching your interest today that we might see you move into over time?

On our long-term guidance of $4.7 billion in portfolio receipts by 2030, we feel really good about where we're tracking. We provided that guidance at our Investor Day and at this stage it's early to consider changes, but we're tracking well and are happy with the portfolio performance and deployment opportunities.

On emerging therapeutic areas, we approach this broadly. We're open to great products in any therapeutic area and in any geography. Our team is set up to analyze and execute across a wide range of categories. We don't impose a top-down constraint; instead, we evaluate opportunities rigorously, and the team is prepared to support and invest in the best products wherever they emerge.

The next question will come from Jason Gerberry with Bank of America.

Following up on China and your patient approach, just thoughts on U.S. policy risk and proposed licensing restrictions. Do you view this as a risk, and is this part of why you are taking a patient approach? Also, regarding milestone dynamics, as we look to the second half, are milestones likely to be a more meaningful contributor given upcoming PDUFAs?

China is a very interesting opportunity because the innovation there is substantial and many companies will need U.S. and European partners to run trials and commercialize in those markets. That creates out-licensing opportunities and thus royalties. Typically, the IP for those deals sits in offshore entities, and the contracts are governed under U.S. or European laws, similar to other transactions we do. Royalties are different from equity investments; royalties are contract-based and generate payments under those contracts. We have done transactions like the Imdelltra acquisition with Amgen that resemble our standard royalty transactions. We are monitoring policy developments, but we believe the royalty model is fundamentally well-suited to engaging with innovation coming out of China.

We are closely monitoring proposed legislation such as the COINS and BINSA acts and amendments. It's early to comment on specifics, but we have a local presence building in China and have hired Ken Sun to lead that effort. The opportunity already exists given several years of out-licensing from Chinese biotech to Western multinationals, and many royalty agreements are already in place regardless of developments in Washington.

On milestones, we continue to expect milestones and other contractual receipts to be around $60 million for the year.

I am showing no further questions at this time. I will now turn the call back to Pablo for closing remarks.

Thank you, operator, and thanks to everyone on the call for your continued interest in Royalty Pharma. Looking back to this business that we've been building over 30 years and our public offering in 2020, it's remarkable how this business has performed with very high consistency in growth, profitability and predictability. As I mentioned, this is our 25th quarter after our IPO. We've delivered predictable strong growth. If anybody has any questions, please feel free to reach out to George Grofik and his team. Thank you very much.

This concludes today's conference call. Thank you for participating, and you may now disconnect.